89zr trastuzumab - a radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium zr 89 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of zirconium zr 89 trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (her2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (pet), thereby allowing the imaging and quantification of her2 expressing tumor cells. Her2, a tyrosine kinase client protein of heat shock protein 90 (hsp90), may be overexpressed on the cell surfaces of various tumor cell types.
Up to date info
Latest research - 89zr trastuzumab
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on 89zr trastuzumab for any updates.